Identification of non-small cell lung cancer biomarkers using mass spectrometry by Gámez-Pozo, A. et al.
Poster S6. Biomarker Discovery and Validation 
P92 
203 
 
IDENTIFICATION OF NON-SMALL CELL LUNG CANCER 
BIOMARKERS USING MASS SPECTROMETRY   
A. Gámez-Pozo
 (1)
, I. Sánchez-Navarro1
 (1)
, E. Calvo
 (2)
, T. Agulló
 (3)
, E. Díaz
 (1)
, E. 
Camafeita
 (2)
, E. Espinosa
 (4)
, J.A. López
 (2)
, M. Nistal
 (5)
, J.A. Fresno Vara
 (1)
. 
(1) 
Laboratory of Molecular Pathology & Oncology, Unidad de Investigación, Hospital 
Universitario La Paz , 
(2) 
Centro Nacional de Investigaciones Cardiovasculares (CNIC), 
(3) 
Unidad 
de Investigación, Hospital Doce de Octubre, 
(4) 
Medical Oncology Unit, Hospital Universitario 
La Paz (IDIPAZ). , 
(5) 
Pathology Unit, Hospital Universitario La Paz (IDIPAZ).. 
With the completion of the human genome sequence, the biomedical sciences 
have entered in the “omics" era. This has been mainly due to the development of high-
throughput genomic techniques, such as microarrays and, in recent days, the application 
of mass spectrometry to proteomic analysis. However, there is still a gap between these 
technological advances and their direct application in the clinical setting. The work 
hereby presented is designed to build bridges between high-performance proteomics and 
clinical routine.  
Protein extracts were obtained from clinical non-small cell lung cancer 
(NSCLC) samples. Using a phosphopeptide enrichment-based approach, we performed 
proteomics analyses based on high resolution mass spectrometry, using an LTQ-
Orbitrap XL mass spectrometer (Thermo Scientific). Subsequent ontological analyses 
and label-free quantification using SIEVE software (Thermo Scientific) were carried 
out. Some of the identified biomarkers were validated using classical proteomics 
techniques. Results were analyzed using several statistical approaches. 
Our results show that it is possible to discriminate normal from tumor tissue and 
between different subtypes of NSCLC using LC-MS/MS. With this technology we were 
able to assess protein and phosphoprotein patterns on these samples, identifying dozens 
of differential markers between normal and tumor tissue, and some markers that 
discriminate between adenocarcinoma and squamous cell carcinoma, the two most 
common histological subtypes of NSCLC. Gene Ontology analyses performed show 
great potential identifying signaling pathways and biological processes susceptible of 
therapeutic intervention, and may provide clues to the genesis of the disease and 
underlying molecular alterations. 
The requirement of a molecular test that complements the classic clinical 
diagnosis of lung cancer has been pinpointed by the results of recently developed 
clinical trials, demonstrating different response patterns to specific drugs according to 
histological subtype. The application of discovery-based proteomics analyses in clinical 
samples allows us to identify new biomarkers and new potential therapeutic targets in 
NSCLC.
